Samantha Di Donato

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Chiara Cremolini, Fotios Loupakis, C. Antoniotti et al. · Annals of Oncology · 2015 · 194 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Emanuela Dell’Aquila, Chiara Cremolini, Tea Zeppola et al. · Annals of Oncology · 2018 · 134 citations · Full text

Medicine, Immunology, Oncology +17

Whole body cholesterol metabolism is impaired in Huntington's disease

Valerio Leoni, Caterina Mariotti, Lorenzo Nanetti et al. · Neuroscience Letters · 2011 · 89 citations

Life Sciences, Biochemistry, Neurology +8

A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Fotios Loupakis, Rossana Intini, Chiara Cremolini et al. · European Journal of Cancer · 2019 · 70 citations · Full text

Medicine, Oncology, Pathology +16